SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: The Dodgy Ticker who wrote (460)1/21/2004 11:17:45 PM
From: Miljenko Zuanic  Read Replies (1) of 1840
 
Bob, in short BS!

Avastin bind VEGF-X, regardless what receptor(s) is overexpressed/active in specific cancer. 2C3 (like SUGN early candidate, and IMCL antibody, and others) is against specific receptor(s), and in many cases can not control angiogenesis or metastases on its own.

Comparing side effects of neutralizing receptor relative to circulating VEGF is like comparing orange and tomato, imo.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News